Vitamin C Attenuates Trichloroacetic Acid-Induced Cardiac Injury and Fibrotic Remodeling in Rats: Biochemical and Histopathological Evidence

Technical Summary: Vitamin C Attenuates Trichloroacetic Acid-Induced Cardiac Injury and Fibrotic Remodeling in Rats

Problem Statement
Trichloroacetic acid (TCA), a significant oxidative metabolite of the industrial solvent trichloroethylene, is known to cause toxic effects in various organs, primarily through oxidative stress and inflammation. While hepatotoxic and nephrotoxic effects of TCA are well-documented, its cardiotoxic potential remains insufficiently characterized. Specifically, the mechanisms by which TCA induces cardiac injury, inflammation, and myocardial fibrosis, and whether these adverse effects can be mitigated by antioxidant therapy, require further investigation. This study addresses the gap in understanding TCA-induced cardiac pathology and evaluates the protective capacity of Vitamin C (ascorbic acid) against such toxicity.

Methodology
The study employed a preclinical animal model using twenty healthy adult female Wistar rats (180 ± 10 g). The animals were randomly assigned to four experimental groups (n=5 per group) and treated orally via gavage for 21 consecutive days:

1. Control: Normal saline (1 mL/day).
2. TCA: Trichloroacetic acid (400 mg/kg/day).
3. Vitamin C: Ascorbic acid (50 mg/kg/day).
4. TCA + Vitamin C: Co-administration of TCA (400 mg/kg/day) and Vitamin C (50 mg/kg/day).

Following the treatment period, serum levels of Interleukin-1β (IL-1β) were quantified using ELISA, and Creatine Phosphokinase (CPK) activity was measured via colorimetric assay. Cardiac tissues were excised, fixed in 10% neutral-buffered formalin, and processed for histopathological analysis.

• Hematoxylin and Eosin (H&E) Staining: Used to evaluate structural alterations, including sarcolemma disruption, necrosis, and fiber separation.
• Masson's Trichrome Staining: Used to visualize and quantify collagen deposition and interstitial fibrosis.
• Quantification: Fibrotic area was quantified using Fiji software (ImageJ) by calculating the collagen-positive area fraction.
• Statistical Analysis: Data were analyzed using GraphPad Prism. One-way ANOVA was used for biochemical markers, Kruskal-Wallis for histopathological scoring, and Nested one-way ANOVA for fibrosis quantification.

Key Contributions and Results
The study provides biochemical and histopathological evidence that TCA induces significant cardiac injury and that Vitamin C offers partial protection against these effects.

• Biochemical Markers:

  • IL-1β: TCA administration significantly elevated serum IL-1β levels (127.5 ± 35.76 pg/mL) compared to controls (6.125 ± 0.4748 pg/mL). Co-administration of Vitamin C significantly reduced IL-1β levels in the TCA+VitC group (76.75 ± 19.07 pg/mL) compared to the TCA-only group (P = 0.0211).
  • CPK Activity: TCA treatment significantly increased serum CPK activity (208.8 ± 17.27 U/L) relative to controls (78.50 ± 11.27 U/L). Vitamin C co-treatment significantly attenuated this elevation (175.5 ± 14.18 U/L; P = 0.0182 vs. TCA).

• Histopathological Findings:

  • Structural Integrity: H&E staining revealed that TCA caused marked myocardial degeneration, sarcolemmal damage, widened intercellular spaces, and pyknotic nuclei. These pathological changes were significantly attenuated in the Vitamin C co-treated group, which showed substantial preservation of normal cardiac morphology.
  • Fibrosis: Masson's Trichrome staining demonstrated extensive collagen accumulation and interstitial fibrosis in the TCA group. Quantitative analysis showed the fibrotic area increased from 5.73 ± 0.55% in controls to 15.53 ± 1.65% in the TCA group (P < 0.0001). Vitamin C treatment significantly reduced fibrosis to 7.33 ± 0.69% (P < 0.0001 vs. TCA).

Significance and Claims
The authors claim that TCA exposure induces cardiac injury characterized by inflammation (elevated IL-1β), tissue damage (elevated CPK), and pathological remodeling (myocardial fibrosis). The study demonstrates that Vitamin C significantly mitigates these adverse effects.

A notable contribution of the paper is the observation regarding Vitamin C's role in fibrosis. While Vitamin C is a known cofactor for collagen biosynthesis (prolyl and lysyl hydroxylases), the authors highlight its paradoxical anti-fibrotic effect under pathological conditions. They propose that Vitamin C attenuates TCA-induced fibrosis through its antioxidant and anti-inflammatory properties, potentially by suppressing pro-fibrotic mediators and ROS-driven pathways, rather than promoting excessive collagen deposition.

The authors conclude that Vitamin C possesses cardioprotective and anti-fibrotic properties against TCA-induced toxicity. However, they maintain a modest stance regarding the underlying mechanisms, explicitly stating that the precise molecular pathways (such as TGF-β signaling) were not investigated in this study and require further elucidation. The findings suggest that Vitamin C may serve as a potential adjunctive therapy for toxin-induced cardiac injury, though the study is limited to an animal model and does not establish clinical applications for humans.